Key Insights on Gross Profit: Takeda Pharmaceutical Company Limited vs Genmab A/S

Takeda vs. Genmab: A Decade of Profit Growth

__timestampGenmab A/STakeda Pharmaceutical Company Limited
Wednesday, January 1, 20148503850001256834000000
Thursday, January 1, 201511330410001271973000000
Friday, January 1, 201618161220001173296000000
Sunday, January 1, 201723654360001274610000000
Monday, January 1, 201830251370001437534000000
Tuesday, January 1, 201953660000002201424000000
Wednesday, January 1, 2020101110000002203504000000
Friday, January 1, 202184820000002462160000000
Saturday, January 1, 2022145950000002783406000000
Sunday, January 1, 2023162480000002832257000000
Monday, January 1, 20242832257000000
Loading chart...

In pursuit of knowledge

A Tale of Two Giants: Takeda vs. Genmab

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and Genmab A/S stand as titans, each with a unique trajectory in gross profit over the past decade. From 2014 to 2023, Takeda's gross profit consistently dwarfed that of Genmab, showcasing a robust growth trajectory. In 2023, Takeda's gross profit reached approximately 2.83 trillion, marking a 125% increase from 2014. Meanwhile, Genmab's journey, though on a smaller scale, is equally impressive. Starting at 850 million in 2014, Genmab's gross profit surged by over 1,800% to 16.25 billion in 2023. This stark contrast highlights Takeda's dominance in scale, while Genmab's rapid growth underscores its dynamic expansion. Notably, data for Genmab in 2024 is missing, leaving room for speculation on its future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025